ear

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial

MARTINSRIED/MUNICH, Germany, July 9, 2007-A virus that has beenspecifically designed by scientists to be safe to normal tissue butdeadly to cancer is showing early promise in a preliminary study,researchers said today at the ESMO Conference Lugano (ECLU),Switzerland. The virus, called NV1020, is a type of herpes simplex virusmodified so that it selectively replicates in virus cells...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

NIEHS Researchers Identify Enzyme Critical in DNA Replication

BETHESDA, Md., July 5, 2007--In this weeks issue of Science,researchers from the National Institute of Environmental HealthSciences (NIEHS) and Umeö University in Sweden report animportant discovery about a critical new role that an enzyme calledDNA polymerase epsilon plays in replicating DNA in higher organismssuch as yeast and perhaps even humans. The study places us one ste...

Stanford Researchers Find Brain Pathway of Depression in Rats

STANFORD, Calif.--(BUSINESS WIRE)--Jul 5, 2007 - Scientists' huntfor the cause of depression has implicated so many suspects andfound so many treatments with different mechanisms that thecondition remains an enigma. Now researchers at the StanfordUniversity School of Medicine have identified one unifyingprinciple that could explain how a range of causes and treatmentsfor depression converge...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials

PHILADELPHIA, July 3, 2007-- Ongoing therapeutic cancer vaccinetrials have yet to show evidence of vaccines spurring apatient’s immune system to shrink tumors -- yet patients whoreceive these vaccines in trials tend to live longer and respondbetter to subsequent treatment. In the July 1 issue of ClinicalCancer Research, a journal of the American Association for CancerResearch, a te...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

PHILADELPHIA, July 3, 2007-- One of the fundamental traits of atumor – how it avoids the immune system – might becomeits greatest vulnerability, according to researchers from theUniversity of Southern California. Their findings,demonstrated in human breast and colorectal cancers, indicate thata technique for determining a tumor’s “immunesignature,” could be...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The University ofPittsburgh School of Health Sciences issued the following study andpress release, "Scientists Culture Blood-Forming Stem Cells fromHuman Fat Tissue," June 15, 2007, Science Daily: "Researchers atthe University of Pittsburgh School of Medicine have successfullyisolated and cultured human hematopoietic stem cells from fat, oradipose...

Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced todaythat Lipitor (atorvastatin calcium) Tablets 80 mg reduced the riskof stroke, coronary heart disease events and major coronary eventsin type 2 diabetes patients who had no known coronary heart diseasebut who had experienced a recent stroke or mini-stroke, comparedwith placebo. The results are from a new analysis of the landmarkSt...

Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes

- BYETTA also Showed Sustained Improvements in Blood GlucoseControl and Progressive Weight Loss - CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. and Eli Lilly and Company today announcedresults from a study that showed BYETTA(R) (exenatide) injectionsustained improvements in blood sugar levels and progressive weightloss through three and a half years of thera...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

New survey shows more than half of infertile couples willing todonate unused embryos for stem cell research BETHESDA, Md., June 20, 2007 /PRNewswire/ -- RESOLVE: TheNational Infertility Association issued the following statementtoday, in anticipation of President Bush's veto of federallegislation that would loosen current limitations on stem cellresearch: "President Bush is choosin...

Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries

WASHINGTON--(BUSINESS WIRE)--Jun 20, 2007 - Today, President BushSigned An Executive Order To Strengthen Our Nation's Commitment ToResearch On Pluripotent Stem Cells. Scientists have recently shownthey have the ingenuity and skill to pursue the potential benefitsof pluripotent stem cell research - research on cells that have thepotential to develop into nearly all the cell types and tissues...

President Bush Ignores America's Plea for Support of Stem Cell Research

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing statement may be attributed to Sean Tipton, president,Coalition for the Advancement of Medical Research (CAMR): "In the face of spiraling health care costs, President Bush onceagain used the stroke of his veto pen deliberately to hamper theprogress of scientific and medical research, as well as endangerthe future hea...

Researchers Discover Gene For Rare Skin Disorder

WASHINGTON, June 20, 2007-Researchers funded in part by theNational Institutes of Health have identified the gene thataccounts for most cases of Goltz syndrome, a rare skin disorderthat can also affect bone and eye development. The cases appear to result from a defect in the gene known asPORCN, which contains the information needed to make a protein,referred to by researchers as porcupine...

The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bush's Veto of the Stem Cell Research Enhancement Act

SHORT HILLS, N.J., June 20, 2007 /PRNewswire-USNewswire/ -- TheChristopher and Dana Reeve Foundation (CDRF), the national,non-profit organization dedicated to finding cures and treatmentsfor spinal cord injuries and improving the lives of people livingwith paralysis, today expressed strong disappointment in PresidentBush's veto of the Stem Cell Research Enhancement Act, which wouldhave p...

Apollo's human proteins boost stem cell research

SYDNEY, Australia, June 21, 2007-At a time when Australianscientists are fighting hard to keep pace with overseas researchand development, an Australian biotech company is leading the worldin the production of human proteins for stem cell research. Apollo CEO John Priest said the company's human proteins areunique in the way they help stem cells to develop into specificcell types s...

Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine

SAN FRANCISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun 21, 2007- The Institute for OneWorld Health, a US-based non-profitpharmaceutical company, today announced that Phase 3 researchrelated to its first approved drug product, Paromomycin IMInjection (Paromomycin), was published in the current issue of TheNew England Journal of Medicine (NEJM). This clinical trial showsthat the medicine...

Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ViralResearch Corp. (OTCBB: ADVR), a research based biopharmaceuticalcompany, announced today that preliminary findings from its ongoingPhase II dermatological study show topical treatment with AVR118appears to have clinical activity in reducing inflammation andredness associated with surgical incisions or dermatologicdermabrasion....

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25/ - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and inducedantiangiotensin II antibody levels - Detailed results presented today at the Seventeenth EuropeanMeeting on Hypertension in Milan, Italy SCHLIEREN (Zurich), Switzerland and MILAN, Ita...

Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen

Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCeptCorporation today announced the results of scientific studies that(1) demonstrate that Azixa(TM) (MPC-6827) is effective in treatingmultiple types of human tumors in animal models, (2) reveal amechanism by which MPC-6827 exerts its effects, and (3) show thatMPC-6827 is not affected b...

Remicade Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation

Findings from the ASSERT Trial Presented at EULAR BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ -- Datapresented today at the European League Against Rheumatism (EULAR)Annual European Congress of Rheumatology showed that patients withankylosing spondylitis (AS) who received REMICADE(R) (infliximab)over two years experienced significant improvement in spinalmobility. In addition,...

Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action

SALT LAKE CITY, June 14, 2007 /PRNewswire/ -- ProlexysPharmaceuticals and announced today a publication describing theproperties of the selective small molecule anti-tumor agent,erastin. Prolexys and Columbia applied the company'schemi-proteomics technology to understand the mechanism of actionof erastin. The results, to be published in the June 14, 2007 issueof the journal Nature reveal...

Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR

THOUSAND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Jun13, 2007 - Amgen (NASDAQ:AMGN) and Wyeth Pharmaceuticals, adivision of Wyeth (NYSE:WYE), today announced the presentation ofadditional data that showed that the safety profile of Enbrel(R)(etanercept) was maintained with long-term use in patients withmoderate-to-severe juvenile rheumatoid arthritis (JRA) whocompleted up to e...

Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia

Data Highlights the Impact of Insomnia on Healthcare System andWorker Productivity SAN DIEGO, June 12, 2007 /PRNewswire-FirstCall/ -- NeurocrineBiosciences, Inc. announced today that results from severalresearch studies on the impact of chronic primary and transientinsomnia were presented this week at the Associated ProfessionalSleep Societies (APSS) Annual Meeting. APSS highlights show t...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed betweenvalopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting ofvalopicitabine (NM283), Idenix's lead dru...

NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans

BETHESDA, Md., June 11, 2007--A team of researchers at theNational Cancer Institute (NCI), part of the National Institutes ofHealth (NIH), has uncovered a set of genes that are turned on, orexpressed, at high levels only in the blood vessels that feedtumors in mice and humans. These genes, and the proteins theyencode, are important new potential targets for novel drugs thatcould selectiv...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - GeronCorporation (Nasdaq:GERN) today announced the presentation ofresearch studies indicating that GRNOPC1, the company's humanembryonic stem cell (hESC)-based therapeutic for the treatment ofspinal cord injury, evades a direct attack by the human immunesystem. Presented by Geron scientist Ross Okamura at the Federation ofClinical Immun...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

- Results Presented at the 12th Congress of European HematologyAssociation (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that data presented at the 12th Congressof EHA in Vienna, Austria, showed positive responses in patie...

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

HAMBURG, Germany, June 11, 2007 /PRNewswire/ -- NovaCardia, Inc.today presented preliminary results from a pilot Phase 3 trial ofKW-3902, an adenosine A1 receptor antagonist in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a strong trend toward efficacy for the 30 milligramdose. Patients treated with KW-3902 experienced a higher rate ofi...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, made a posterpresentation at the 2007 Annual Meeting of the Federation ofClinical Immunology Societies (FOCIS) in San Diego June 7-11 at theSheraton San Diego Hotel & Marina. The poster, entitled"Identifying New Immuno...

Promising Data on Cognitive Effects of Safinamide in Early Parkinson's Disease

• Data presented at Movement Disorder Society’s 11thInternational Congress • Management of cognitive impairment in earlyParkinson’s disease patients is a critical unmet medicalneed Geneva, Switzerland, June 8, 2007 – Merck Serono S.A.(virt-x: SEO) and its partner Newron Pharmaceuticals S.p.a. (SWX:NWRN) announced today data, which suggest tha...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...